Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The main purpose of the study is to:
- Determine the safety and tolerability of erlotinib and LBH589B.
- Establish a recommended phase II expansion dosing of LBH589B and erlotinib in patients
with advanced aerodigestive tract cancers.
Phase:
Phase 1
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute